P
Poolbeg Pharma PLC
LSE:POLB
Poolbeg Pharma PLC
LSE:POLB
Price:
4.5
GBX
8.43%
Market Closed
Market Cap:
£31.4m
Relative Value
There is not enough data to reliably calculate the relative value of POLB.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
POLB
Relative Value
Base Case
Not Available
P
Multiples Across Competitors
POLB Competitors Multiples
Poolbeg Pharma PLC Competitors
Poolbeg Pharma PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
P
|
Poolbeg Pharma PLC
LSE:POLB
|
31.4m GBP | 0 | -5.5 | -3.7 | -3.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
929B USD | 14.3 | 45.1 | 30.3 | 32.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.1B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.3B CHF | 4.2 | 19.8 | 11.7 | 13.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.5B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.3B GBP | 5.1 | 29.3 | 16.3 | 22.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
285B USD | 4.4 | 15.6 | 9.7 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.7 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD | 2.4 | 19.4 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
